By means of multivariate logistic regression analysis, we built a combined biomarker model of these three circulating biomarkers (platelet count, IL-15 and GM-CSF) that discriminates metastatic PDAC from non-metastatic disease. This evidence concerns the gene CSF2 and metastatic neoplasm.